Oslo, Norway, 30 April 2024: Photocure ASA today announces the publication of
the Annual Report and integrated ESG report for 2023.
The Board of Directors of Photocure ASA has approved the annual accounts for
2023. The financial statements and annual report for the financial year 2023 are
together with the ESG report and auditor's report attached to this notice. The
ESEF file for 2023 is also attached.
The documents are enclosed and also made available at the company's website
under https://photocure.com/investors-hub/investors-events-and-presentations.
For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com
About Photocure ASA:
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA. This information is subject to the disclosure
requirements pursuant to sections 5-12 of the Norwegian Securities Trading Act.